The proposed combination marries Veea's expertise in computing and security with NovaGen's clinical services and cellular reprogramming capabilities. GeoNova Capital has committed to an initial $10 million investment, contingent upon the successful closure of the deal and the finalization of definitive legal documentation.

The venture will roll out in two distinct stages. Initially, the platform will deploy private household health hubs featuring patient-controlled data wallets. These hubs are designed to process sensitive information locally while supporting AI-driven wellness tools, medication management, and secure provider sharing. The second phase integrates digital twins and biopsy-derived cellular data to identify candidates for NovaGen’s personalized longevity and regenerative treatments. Investors responded sharply to the strategy, driving Veea's stock price from a regular session close of $2.29 to $3.23.